July 02, 2025

Metabolic Syndrome Strongly Linked to Oral Diseases

New research highlights strong associations between metabolic syndrome and several oral diseases—including periodontitis, caries, and peri-implantitis—calling for more longitudinal studies to explore causation and improve patient care.

Conexiant

July 01, 2025

Five Gynecologic Conditions Linked with Bladder Pain

A new international consensus identifies five gynecologic conditions commonly linked with interstitial cystitis/bladder pain syndrome, urging clinicians to adopt a multidisciplinary and trauma-informed approach to care.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

Gout and Ultrasound Predict Carotid Risk

Ultrasound features and gout flares help identify patients at risk for carotid plaque vulnerability, a key factor in stroke risk.

Conexiant

June 26, 2025

First Targeted Therapy Approved for BP

The FDA has approved dupilumab as the first targeted treatment for adults with bullous pemphigoid, showing improved remission rates and reduced corticosteroid use.

Conexiant

June 25, 2025

Top Physical Therapies for Knee OA

A large-scale analysis of physical therapies for knee osteoarthritis found knee bracing, hydrotherapy, and exercise to be the most effective options for reducing pain and improving function.

Conexiant

June 24, 2025

Dermatologists Show Lowest Turnover Intent of All Specialists

AMA data show only 19.9% of dermatologists plan to leave their current positions, compared with 40.6% of anesthesiologists.

Conexiant

June 24, 2025

Do CBC Ratios Predict RA Mortality?

Elevated SIRI, NLR, and MLR from routine blood counts independently predicted higher all-cause mortality among patients with rheumatoid arthritis.

Conexiant

June 24, 2025

FDA Approves At-Home Lupus Nephritis Therapy

The FDA has approved a subcutaneous autoinjector of belimumab for at-home treatment of pediatric lupus nephritis.

Conexiant